ArticleMayo Clinic proceedings. Digital health2026
Clinical Translatable and Transparency of Neural Network for Blood-Based Personalized Cancer Risk.
Article in Mayo Clinic proceedings. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To support cancer screening and identify precancerous conditions, such as atypical hyperplasia, to improve cure rates and reduce mortality, by analyzing the performance of a previously confirmed procedure. Patients and Methods: We established 204 short-term blood-derived cell lines from patients with cancer between December 1, 2013 and December 31, 2022. A dataset of phenotypic patterns, cytopathological variables, and proliferation profiles was used to train a neural network model. Comparative analysis of standard optical, functional, and machine learning supported diagnosis was performed to verify reproducibility and clinical translatability. Results: Tumor heterogeneity was classified into 7 phenotypic patterns (Pn1-Pn7); the Pn6-7 group showed an overall survival of 8 months (95% CI, 6-9). Among variables Vc1-Vc8, Vc3 (area under the curve=1, Conclusion: The model demonstrated fast adaptive performance in predicting cancer risk and primary source assessment. The results suggest that this screening model is sufficient to detect atypical hyperplasia compared with models based on oligoanalysis for single or double mutations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.